NephrologyOnline.net

Nephrology Xagena

Search results for "Chronic kidney disease"

The FDA ( Food and Drug Administration ) has approved Zemplar ( Paricalcitol ) capsules, an oral, activated vitamin D therapy for prevention and treatment of secondary hyperparathyroidism ( SHPT ). ...


A study by researchers at the Johns Hopkins Bloomberg School of Public Health and other institutions, found two common gene variations are associated with the risk for developing chronic kidney disea ...


A Mayo Clinic study found men who experience signs and symptoms of a prostate obstruction resulting from benign prostatic hyperplasia ( BPH ) are three times more likely than other men to develop chr ...


Large, for-profit dialysis facilities appear to administer higher than necessary amounts of a medication for treating anemia in patients with kidney disease, compared to nonprofit facilities, accord ...


Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent ( ESA ), is a potential therapy for anemia in patients with advanced chronic kidney disease.Researchers have conducted two rand ...


Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the useful ...


Results from the FIND-CKD study were presented at the American Society of Nephrology ( ASN ) Kidney Week in Atlanta, Georgia, USA. The FIND-CKD results have shown that Ferinject ( Ferric carboxymaltos ...


Tolvaptan ( Samsca ), a diuretic with a new mechanism of action, selectively binds to the vasopressin V2 receptor and inhibits reabsorption of water. Its effect on heart failure is proven, but its ben ...


Vasopressin V2-receptor antagonists may delay disease progression in autosomal dominant polycystic kidney disease ( ADPKD ). Trials with V2-receptor antagonists have been performed predominantly i ...


Tolvaptan ( Samsca ), a diuretic with a new mechanism of action, selectively binds to the vasopressin V2 receptor and inhibits reabsorption of water. Its effect on heart failure is proven, but its ben ...


Autosomal dominant polycystic kidney disease ( ADPKD ) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to ...


Serum Alkaline phosphatase ( ALP ) & phosphate are considered to be indicators of vascular calcification. Link between bone metabolism, vascular calcification, cardiovascular events have been well ...


Abnormal mineral metabolism is a hallmark in patients with advanced chronic kidney disease ( CKD ). Hyperphosphatemia, and the homeostatic mechanisms controlling phosphate metabolism, have received pa ...


The concept of chronic kidney disease - mineral bone disorder ( CKD-MBD ) does not appear to fulfil the requirements for a syndrome at first glance, but its definition has brought some clear-cut benef ...


In phase 4 IMPACT-SHPT study, efficacy and safety of Paricalcitol-centred therapy were compared with that of Cinacalcet-centred therapy for the treatment of chronic kidney disease (CKD)-associated sec ...